Alterations in the striatal dopamine system during intravenous methamphetamine exposure: Effects of contingent and noncontingent administration

Synapse

Volumn 67, Issue 8, 2013, Pages 476-488

  Laćan, Goran ^a   Hadamitzky, Martin ^b   Kuczenski, Ronald ^b   Melega, William P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Binges; Dopamine transporter; Self administration; Striatum; Tolerance

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); METHAMPHETAMINE; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG BLOOD LEVEL; DRUG HALF LIFE; MALE; METHAMPHETAMINE DEPENDENCE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BINDING;

ANIMALS; CORPUS STRIATUM; DOPAMINE AGENTS; DOPAMINE AGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; METHAMPHETAMINE; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; SUBSTANTIA NIGRA; SULFUR RADIOISOTOPES; TRITIUM; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84879555731     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21654     Document Type: Article

References (60)

1. Angrist B. 1983. Stimulants: Neurochemical, behavioral and clinical perspectives. Creese I, editor. New York: Raven Press.
2. Cadet JL, McCoy MT, Cai NS, Krasnova IN, Ladenheim B, Beauvais G, Wilson N, Wood W, Becker KG, Hodges AB. 2009. Methamphetamine preconditioning alters midbrain transcriptional responses to methamphetamine-induced injury in the rat striatum. PLoS One 4:e7812.
3. Cho AK, Melega WP, Kuczenski R, Segal DS. 2001. Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse 39:161-166.
4. Coulter CL, Happe HK, Bergman DA, Murrin LC. 1995. Localization and quantification of the dopamine transporter: Comparison of [3H]WIN 35, 428 and [125I]RTI-55. Brain Res 690:217-224.
5. Curran C, Byrappa N, McBride A. 2004. Stimulant psychosis: Systematic review. Br J Psychiatry 185:196-204.
6. Danaceau JP, Deering CE, Day JE, Smeal SJ, Johnson-Davis KL, Fleckenstein AE, Wilkins DG. 2007. Persistence of tolerance to methamphetamine-induced monoamine deficits. Eur J Pharmacol 559:46-54.
7. Darchen F, Masuo Y, Vial M, Rostene W, Scherman D. 1989. Quantitative autoradiography of the rat brain vesicular monoamine transporter using the binding of [3H]dihydrotetrabenazine and 7-amino-8-[125I]iodoketanserin. Neuroscience 33:341-349.
8. Davidson C, Gow AJ, Lee TH, Ellinwood EH. 2001. Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 36:1-22.
9. Everitt BJ, Belin D, Economidou D, Pelloux Y, Dalley JW, Robbins TW. 2008. Review. Neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction. Philos Trans R Soc Lond B Biol Sci 363:3125-3135.
10. Frankel PS, Hoonakker AJ, Alburges ME, McDougall JW, McFadden LM, Fleckenstein AE, Hanson GR. 2011. Effect of methamphetamine self-administration on neurotensin systems of the basal ganglia. J Pharmacol Exp Ther 336:809-815.
11. Ghitza UE, Fabbricatore AT, Prokopenko V, Pawlak AP, West MO. 2003. Persistent cue-evoked activity of accumbens neurons after prolonged abstinence from self-administered cocaine. J Neurosci 23:7239-7245.
12. Gustavsen I, Morland J, Bramness JG. 2006. Impairment related to blood amphetamine and/or methamphetamine concentrations in suspected drugged drivers. Accid Anal Prev 38:490-495.
13. Hadamitzky M, Markou A, Kuczenski R. 2011. Extended access to methamphetamine self-administration affects sensorimotor gating in rats. Behav Brain Res 217:386-390.
14. Hadamitzky M, McCunney S, Markou A, Kuczenski R. 2012. Development of stereotyped behaviors during prolonged escalation of methamphetamine self-administration in rats. Psychopharmacology (Berl) 223:259-269.
15. Hart CL, Marvin CB, Silver R, Smith EE. 2012. Is cognitive functioning impaired in methamphetamine users? A critical review. Neuropsychopharmacology 37:586-608.
16. Harvey DC, Lacan G, Tanious SP, Melega WP. 2000. Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res 871:259-270.
17. Hyman SE, Malenka RC, Nestler EJ. 2006. Neural mechanisms of addiction: The role of reward-related learning and memory. Annu Rev Neurosci 29:565-598.
18. Iyo M, Nishio M, Itoh T, Fukuda H, Suzuki K, Yamasaki T, Fukui S, Tateno Y. 1993. Dopamine D2 and serotonin S2 receptors in susceptibility to methamphetamine psychosis detected by positron emission tomography. Psychiatry Res 50:217-231.
19. Johanson CE, Frey KA, Lundahl LH, Keenan P, Lockhart N, Roll J, Galloway GP, Koeppe RA, Kilbourn MR, Robbins T, Schuster CR. 2006. Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology (Berl) 185:327-338.
20. Johnson-Davis KL, Truong JG, Fleckenstein AE, Wilkins DG. 2004. Alterations in vesicular dopamine uptake contribute to tolerance to the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther 309:578-586.
21. Jones AW, Holmgren A, Kugelberg FC. 2008. Driving under the influence of central stimulant amines: Age and gender differences in concentrations of amphetamine, methamphetamine, and ecstasy in blood. J Stud Alcohol Drugs 69:202-208.
22. Krasnova IN, Justinova Z, Ladenheim B, Jayanthi S, McCoy MT, Barnes C, Warner JE, Goldberg SR, Cadet JL. 2010. Methamphetamine self-administration is associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat. PLoS One 5:e8790.
23. Krasnova IN, Ladenheim B, Hodges AB, Volkow ND, Cadet JL. 2011. Chronic methamphetamine administration causes differential regulation of transcription factors in the rat midbrain. PLoS One 6:e19179.
24. Kuczenski R, Segal DS, Melega WP, Lacan G, McCunney SJ. 2009. Human methamphetamine pharmacokinetics simulated in the rat: Behavioral and neurochemical effects of a 72-h binge. Neuropsychopharmacology 34:2430-2441.
25. Logan BK, Fligner CL, Haddix T. 1998. Cause and manner of death in fatalities involving methamphetamine. J Forensic Sci 43:28-34.
26. Madras BK, Fahey MA, Bergman J, Canfield DR, Spealman RD. 1989a. Effects of cocaine and related drugs in nonhuman primates. I. [3H]cocaine binding sites in caudate-putamen. J Pharmacol Exp Ther 251:131-141.
27. Madras BK, Spealman RD, Fahey MA, Neumeyer JL, Saha JK, Milius RA. 1989b. Cocaine receptors labeled by [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane. Mol Pharmacol 36:518-524.
28. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. 1998. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: Evidence from positron emission tomography studies with [11C]WIN-35, 428. J Neurosci 18:8417-8422.
29. McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, Di Monte DA. 2002. Environmental risk factors and Parkinson's disease: Selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 10:119-127.
30. McFadden LM, Hadlock GC, Allen SC, Vieira-Brock PL, Stout KA, Ellis JD, Hoonakker AJ, Andrenyak DM, Nielsen SM, Wilkins DG, Hanson GR, Fleckenstein AE. 2012. Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure. J Pharmacol Exp Ther 340:295-303.
31. Melega WP, Cho AK, Harvey D, Lacan G. 2007. Methamphetamine blood concentrations in human abusers: Application to pharmacokinetic modeling. Synapse 61:216-220.
32. Melega WP, Jorgensen MJ, Lacan G, Way BM, Pham J, Morton G, Cho AK, Fairbanks LA. 2008. Long-term methamphetamine administration in the vervet monkey models aspects of a human exposure: Brain neurotoxicity and behavioral profiles. Neuropsychopharmacology 33:1441-1452.
33. Nader MA, Daunais JB, Moore T, Nader SH, Moore RJ, Smith HR, Friedman DP, Porrino LJ. 2002. Effects of cocaine self-administration on striatal dopamine systems in rhesus monkeys: Initial and chronic exposure. Neuropsychopharmacology 27:35-46.
34. O'Connor KA, Gregg TC, Davies HM, Childers SR. 2005a. Effects of long-term biogenic amine transporter blockade on receptor/G-protein coupling in rat brain. Neuropharmacology 48:62-71.
35. O'Connor KA, Porrino LJ, Davies HM, Childers SR. 2005b. Time-dependent changes in receptor/G-protein coupling in rat brain following chronic monoamine transporter blockade. J Pharmacol Exp Ther 313:510-517.
36. O'Neil ML, Kuczenski R, Segal DS, Cho AK, Lacan G, Melega WP. 2006. Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge. Synapse 60:465-473.
37. Paxinos G, Watson C. 2005. The rat brain in stereotaxic coordinates. San Diego: Elsevier Academic Press.
38. Rinken A, Finnman UB, Fuxe K. 1999. Pharmacological characterization of dopamine-stimulated [35S]-guanosine 5′(gamma-thiotriphosphate) ([35S]GTPgammaS) binding in rat striatal membranes. Biochem Pharmacol 57:155-162.
39. Schwendt M, Rocha A, See RE, Pacchioni AM, McGinty JF, Kalivas PW. 2009. Extended methamphetamine self-administration in rats results in a selective reduction of dopamine transporter levels in the prefrontal cortex and dorsal striatum not accompanied by marked monoaminergic depletion. J Pharmacol Exp Ther 331:555-562.
40. Segal DS, Kuczenski R. 1987. Individual differences in responsiveness to single and repeated amphetamine administration: Behavioral characteristics and neurochemical correlates. J Pharmacol Exp Ther 242:917-926.
41. Segal DS, Kuczenski R. 1997. Repeated binge exposures to amphetamine and methamphetamine: Behavioral and neurochemical characterization. J Pharmacol Exp Ther 282:561-573.
42. Segal DS, Kuczenski R. 2006. Human methamphetamine pharmacokinetics simulated in the rat: Single daily intravenous administration reveals elements of sensitization and tolerance. Neuropsychopharmacology 31:941-955.
43. Segal DS, Kuczenski R, O'Neil ML, Melega WP, Cho AK. 2003. Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology 28:1730-1740.
44. Segal DS, Kuczenski R, O'Neil ML, Melega WP, Cho AK. 2005. Prolonged exposure of rats to intravenous methamphetamine: Behavioral and neurochemical characterization. Psychopharmacology (Berl) 180:501-512.
45. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Takei N, Mori N. 2001. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158:1206-1214.
46. Sibley DR, Monsma FJ Jr. 1992. Molecular biology of dopamine receptors. Trends Pharmacol Sci 13:61-69.
47. Sim LJ, Selley DE, Childers SR. 1995. In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding. Proc Natl Acad Sci U S A 92:7242-7246.
48. Simon SL, Richardson K, Dacey J, Glynn S, Domier CP, Rawson RA, Ling W. 2002. A comparison of patterns of methamphetamine and cocaine use. J Addict Dis 21:35-44.
49. Sleipness EP, Jansen HT, Schenk JO, Sorg BA. 2008. Time-of-day differences in dopamine clearance in the rat medial prefrontal cortex and nucleus accumbens. Synapse 62:877-885.
50. Stanwood GD, Artymyshyn RP, Kung MP, Kung HF, Lucki I, McGonigle P. 2000a. Quantitative autoradiographic mapping of rat brain dopamine D3 binding with [(125)I]7-OH-PIPAT: Evidence for the presence of D3 receptors on dopaminergic and nondopaminergic cell bodies and terminals. J Pharmacol Exp Ther 295:1223-1231.
51. Stanwood GD, Lucki I, McGonigle P. 2000b. Differential regulation of dopamine D2 and D3 receptors by chronic drug treatments. J Pharmacol Exp Ther 295:1232-1240.
52. Stefanski R, Lee SH, Yasar S, Cadet JL, Goldberg SR. 2002. Lack of persistent changes in the dopaminergic system of rats withdrawn from methamphetamine self-administration. Eur J Pharmacol 439:59-68.
53. Steketee JD, Kalivas PW. 2012. Drug wanting: Behavioral sensitization and relapse to drug-seeking behavior. Pharmacol Rev 63:348-365.
54. Volkow ND, Chang L, Wang GJ, Fowler JS, Ding YS, Sedler M, Logan J, Franceschi D, Gatley J, Hitzemann R, Gifford A, Wong C, Pappas N. 2001. Low level of brain dopamine D2 receptors in methamphetamine abusers: Association with metabolism in the orbitofrontal cortex. Am J Psychiatry 158:2015-2021.
55. Volkow ND, Tomasi D, Wang GJ, Telang F, Fowler JS, Logan J, Benveniste H, Kim R, Thanos PK, Ferre S. 2012. Evidence that sleep deprivation downregulates dopamine D2R in ventral striatum in the human brain. J Neurosci 32:6711-6717.
56. West MJ. 2002. Design-based stereological methods for counting neurons. Prog Brain Res 135:43-51.
57. West MJ, Slomianka L, Gundersen HJ. 1991. Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231:482-497.
58. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ. 1996. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699-703.
59. Worsley JN, Moszczynska A, Falardeau P, Kalasinsky KS, Schmunk G, Guttman M, Furukawa Y, Ang L, Adams V, Reiber G, Anthony RA, Wickham D, Kish SJ. 2000. Dopamine D1 receptor protein is elevated in nucleus accumbens of human, chronic methamphetamine users. Mol Psychiatry 5:664-672.
60. Zhu C, Vourc'h P, Fernagut PO, Fleming SM, Lacan S, Dicarlo CD, Seaman RL, Chesselet MF. 2004. Variable effects of chronic subcutaneous administration of rotenone on striatal histology. J Comp Neurol 478:418-426.